Ensoma

Ensoma CEO Jim Burns joined leaders across biotech at #BIO2026 for conversations on the future of genetic medicine and therapeutic innovation.

It was an energizing week in San Diego, and we're proud to be part of a community advancing the possibilities of genetic medicine.

CEO Jim Burns will join leaders from @KitePharma, @FredHutch, @ChildrensPhila, and @RTWInstitute at #BIO2026 to discuss the future of in vivo HSC engineering and one-time genetic medicines. Learn more: convention.bio.org/2026-sessions-…

The Ensoma team recently gathered at Flight Club Boston for a fun evening of connection, conversation, and friendly competition. We're grateful for opportunities to spend time together and strengthen the relationships that support our work every day.

It was an impactful week at #ASGCT2026 connecting with researchers, clinicians, advocates, and the gene and #celltherapy community. We’re grateful to be part of a community committed to advancing new therapies for patients and their loved ones.

Today, we announced the presentation of initial clinical data from the 1st participant dosed in our Phase 1/2 trial for X-CGD at #ASGCT2026. The data represent the first reported clinical experience with an in vivo hematopoietic stem cell-directed therapy. ensoma.com/press-release/…